Comparison of Pregnancy and Hyperstimulation Syndrome Rate with GnRH Agonist and HCG in Ovation induction of PCOS

Document Type : Original Article

Authors

1 Assistant Professor of Gynecology, Infertility, Babol University of Medical Sciences, Babol, Iran/Fateme-Zahra Infertility Research Center, Babol, Iran

2 Associate Professor of Gynecology, Infertility, Babol University of Medical Sciences, Babol, Iran Fateme-Zahra Infertility Research Center, Babol, Iran

Abstract

Introduction: Infertile women with induction ovulation that have appropriate follicules, need LH surge to release eggs, this is done routinely by HCG. This study designed to compare the pregnancy rate and hyper stimulation syndrome in PCOS patients with GnRH agonist instead of HCG.
Material and Methods: This descriptive study performed from 2003 to 2004 on 130 infertile patients with PCOS at Babol Infertility Center, Babol, Iran. This study was approved by the local committee of medical ethics. After induction ovulation if patients had 2 Follicules more than 16 mm or 3 folliculs more than 14 mm, we randomly used HCG or GnRH agonist for LH surge. The pregnancy rate and hyperstimulation syndrome evaluated. Data analyzed by spss.
Results: There were79 patients in HCG group and 44 patients in GnRH agonist group. There was no significante difference between HCG and GnRH agonist group, with regard to the mean age, infertility duration, number of HCG injection, body mass index and type of infertility (p>0.05). Over all 7(8.9%) patients in HCG group and 3(6.8%) in GnRH agonist group had ovarian hyperstimulation syndrome (p= 0.49). There was pregnancy in 35 (44.3%) patients of HCG group and in 20 (45.5%) patients of GnRH agonist group (p= 0.526).
Conclusion: There was no significant difference in the rate of pregnancy and ovarian hyperstimulation in patients with polycystic ovary, having induction ovulation with HCG and GnRH agonist. So it can be concluded we can say that: GnRH can be used instead of HCG for doing LH surge in PCO patients.

Keywords

References

1. Steven R, Bayer MD, Michael M. Alper MD, Alan S. Penzias MD. The Boston IVF hand book
of infertility. Parthenon publishers; 2002. 1-23.
2. Cluroe AD, Synek BJ. A fatal case of ovarian hyperstimulation syndrome with cerebral
infarction. Pathology 1995; 27: 344-6.
3. Lyons CA, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning RV Jr . Early and
late presentation of the ovarian hyperstimulation syndrome: Two distinct entities with different
risk factors. Hum Reprod 1994; 9: 792 – 9.
4. Delvigne A, Demoulin A,Smitz J, Koninckx P, Dhont M. The Ovarian hyper stimulation
syndrome in in-vitro fertilization:a Belgian multicentric study.I.clinical and biological
features.Hum Report 1993; 8:1353 -60 .
5. Mizunuma H, Andoh K Yamada K, Tajagi T, Kamijo T, Ibuki Y. Prediction and prevention of
ovarian hyperstimulation by monitoring endogenous luteinizing hormone release during purified
follicle-stimulating hormone therapy. Fertile Sterile 1992; 58: 46-50.
6. Gustofson RL, Larsen FW, Bush MR, Segars JH. Treatment with gonadotropin – releasing
hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle
cancellation in patients at risk for ovarian hyperstimulation syndrome. Fertil Steril 2006; 85(1):
251-4.
7. Enskog A, Henriksson M, Unander M, Nilsson L, Brannstrom M. Prospective study of the
clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome
developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil sterile
1999; 71: 808 -14.
8. Buyalos RP, Lee CT. Polycystic ovary syndrome: pathophysiology and outcome with in vitro
fertilization. Fertil Steril 1996; 65:1- 10.
9. Steures P, Berkhout JC, Hompes PG. Patients' preferences in deciding between intrauterine
insemination and expectant management . Hum Reprod 2005; 20(3): 752-5.
10. Avrech OM, 0rvieto R, Pinkas H. Inclusion of standard and low – dose gonadotropin releasing 

11. hormone analog in controlled ovarian hyperstimulation regimens in normogonadotropic patients
age 40–48 y who are under going in vitro Fertilization. Gynecol Endocerrical 2004; 19 (5): 247
– 52.
12. Dehghani firoozabadi R, Aflatoonian E. Hyperstimulation syndrome rate in patients referring
to fertility and infertility research center and evaluation of medical treatment and it s results.
Abstract of infertility researches in Iran 2000; 1:89.
13. Tehraninejad ASH, Madani T, Ramzannejad F. Comparison of induction ovulation in inducted
cycles by Gonadotron with HCG and GnRH. Abstract of infertility researches in Iran 2001;
1:268.
14. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention
of ovarian hyperstimulation syndrome. Fertile Sterile 2004; 81(1):1-5.
15. Raziel A, Friedler S, Schachter M, Strassburger D, Mordechai E. Increased early pregnancy loss in
IVF patients with severe ovarian hyperstimulation syndrome. Hum Reprod 2002; 17(1):107-10.
16. Lazon A, Fulghesu AM, Villa P. Gonadotropin-releasing hormone agonist versus chorionic
gonadotropin as a trigger of ovulation in polycyctic ovarian disease gonadotropin
hyperstimulated cycles. Fertile Sterill 1994; 62(1):35-41. 

Files

Share

How to cite

Statistics